Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
$13.75
$13.74
$4.41
$13.80
$477.47M0.89950,664 shsN/A
CymaBay Therapeutics, Inc. stock logo
CBAY
CymaBay Therapeutics
$32.48
$32.44
$7.26
$32.50
$3.73B0.324.11 million shs73 shs
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$30.30
+2.5%
$28.98
$23.23
$42.29
$950.14M0.64398,219 shs267,653 shs
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$2.36
+4.0%
$1.93
$0.40
$3.10
$183.01M2.052.19 million shs2.57 million shs
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$50.21
-9.2%
$48.97
$32.50
$60.60
$3.43B2.26890,675 shs1.51 million shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CymaBay Therapeutics, Inc. stock logo
CBAY
CymaBay Therapeutics
0.00%0.00%0.00%0.00%0.00%
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
-1.20%-1.04%+0.61%+0.61%-8.17%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
+0.89%+5.09%-9.92%+291.38%+86.07%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-0.75%+3.58%+16.90%+17.90%+59.51%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CymaBay Therapeutics, Inc. stock logo
CBAY
CymaBay Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
4.0185 of 5 stars
3.41.00.03.01.60.82.5
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
4.2104 of 5 stars
3.51.00.04.72.41.71.3
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
1.7412 of 5 stars
3.51.00.00.01.42.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
0.00
N/AN/AN/A
CymaBay Therapeutics, Inc. stock logo
CBAY
CymaBay Therapeutics
0.00
N/AN/AN/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
2.75
Moderate Buy$43.7544.39% Upside
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
3.00
Buy$5.33125.99% Upside
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
3.00
Buy$66.1031.65% Upside

Current Analyst Ratings Breakdown

Latest COLL, CBAY, AMAG, CTMX, and PTGX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$72.00
6/3/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00
5/19/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
5/15/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$2.50 ➝ $5.00
5/15/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$5.00 ➝ $5.00
5/12/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$5.00 ➝ $6.00
5/9/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$36.00 ➝ $37.00
4/14/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight ➝ Overweight$3.25 ➝ $2.50
4/10/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
4/9/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$46.00 ➝ $46.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
$327.75M1.46N/AN/A$7.37 per share1.87
CymaBay Therapeutics, Inc. stock logo
CBAY
CymaBay Therapeutics
$31.07M119.92N/AN/A$2.58 per share12.59
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$631.45M1.54$12.63 per share2.40$7.10 per share4.27
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$138.10M1.38$0.38 per share6.27($0.01) per share-236.00
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$434.43M7.16$4.10 per share12.24$11.33 per share4.43
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
-$466.46M-$6.88N/A76.39N/A-74.93%-16.92%-5.96%N/A
CymaBay Therapeutics, Inc. stock logo
CBAY
CymaBay Therapeutics
-$105.37M-$0.97N/AN/AN/AN/A-50.72%-31.04%N/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$69.19M$1.2224.845.03N/A6.61%99.08%15.14%8/6/2025 (Estimated)
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$31.87M$0.484.92N/AN/A28.22%-553.71%32.21%8/14/2025 (Estimated)
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$275.19M$0.7566.95N/AN/A27.04%9.22%8.31%8/5/2025 (Estimated)

Latest COLL, CBAY, AMAG, CTMX, and PTGX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$0.18$0.27+$0.09$0.27$35.42 million$50.92 million
5/8/2025Q1 2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$1.50$1.49-$0.01$0.07$174.96 million$177.76 million
5/6/2025Q1 2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-$0.50-$0.19+$0.31-$0.19$30.44 million$28.32 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
N/AN/AN/AN/AN/A
CymaBay Therapeutics, Inc. stock logo
CBAY
CymaBay Therapeutics
N/AN/AN/AN/AN/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/AN/AN/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/AN/AN/AN/AN/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
1.13
1.75
1.45
CymaBay Therapeutics, Inc. stock logo
CBAY
CymaBay Therapeutics
N/A
10.96
10.96
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
3.30
1.08
1.01
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/A
1.73
1.73
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/A
17.25
17.26
CompanyEmployeesShares OutstandingFree FloatOptionable
AMAG Pharmaceuticals, Inc. stock logo
AMAG
AMAG Pharmaceuticals
44034.73 millionN/AOptionable
CymaBay Therapeutics, Inc. stock logo
CBAY
CymaBay Therapeutics
101114.72 million106.69 millionOptionable
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
21032.13 million31.33 millionOptionable
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
17080.62 million75.30 millionOptionable
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
12061.98 million58.95 millionOptionable

Recent News About These Companies

PTGX Protagonist Therapeutics, Inc. - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AMAG Pharmaceuticals stock logo

AMAG Pharmaceuticals NASDAQ:AMAG

AMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

CymaBay Therapeutics stock logo

CymaBay Therapeutics NASDAQ:CBAY

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.

Collegium Pharmaceutical stock logo

Collegium Pharmaceutical NASDAQ:COLL

$30.30 +0.73 (+2.47%)
Closing price 04:00 PM Eastern
Extended Trading
$30.30 0.00 (-0.02%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

CytomX Therapeutics stock logo

CytomX Therapeutics NASDAQ:CTMX

$2.36 +0.09 (+3.96%)
Closing price 04:00 PM Eastern
Extended Trading
$2.35 -0.01 (-0.64%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Protagonist Therapeutics stock logo

Protagonist Therapeutics NASDAQ:PTGX

$50.21 -5.06 (-9.16%)
Closing price 04:00 PM Eastern
Extended Trading
$50.24 +0.02 (+0.05%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.